Scottish Medicines Consortium
Providing advice about the status of all newly licensed medicines
www.scottishmedicines.org.uk
Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Angela Timoney FRPharmS
NHS SCOTLAND

Product Update

etanercept 10mg and 25mg powder and solvent for solution for injection for paediatric use, 25mg and 50mg solution for injection in pre-filled syringe, 50mg solution for injection in pre-filled pen (Enbrel®)

(No: 842/13)

Pfizer Ltd

11 January 2013

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

etanercept (Enbrel®) is accepted for restricted use within NHS Scotland.

Indication under review: for the treatment of

- polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;
- psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate;
- enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy.

SMC restriction: use within specialist rheumatology services (including those working within the network for paediatric rheumatology).

Etanercept has previously been accepted by the SMC for the treatment of active polyarticular juvenile idiopathic arthritis in children and adolescents from the age of 2 years who have had an inadequate response to, or who have proved intolerant of, methotrexate.

Etanercept is listed in the British National Formulary for Children 2011-2012 as one of a number of treatment options for juvenile idiopathic arthritis including the above subtypes.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 07 December 2012.

Chairman
Scottish Medicines Consortium